Profile data is unavailable for this security.
About the company
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
- Revenue in USD (TTM)593.00k
- Net income in USD-45.88m
- Incorporated2009
- Employees31.00
- LocationCardiff Oncology Inc11055 Flintkote AveSAN DIEGO 92121-1220United StatesUSA
- Phone+1 (858) 952-7570
- Fax+1 (858) 217-4768
- Websitehttps://cardiffoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 119.10m | 33.00 | -- | 0.972 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 182.33k | -108.09m | 119.54m | 134.00 | -- | -- | -- | 655.65 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
| Agenus Inc | 106.83m | -35.38m | 120.71m | 316.00 | -- | -- | -- | 1.13 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 121.83m | 97.00 | -- | 1.13 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| MacroGenics Inc | 127.63m | -75.89m | 122.72m | 341.00 | -- | 1.83 | -- | 0.9616 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 123.38m | 32.00 | -- | 4.65 | -- | 3.04 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Genelux Corp | 0.00 | -31.87m | 130.56m | 24.00 | -- | 5.91 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.4943 | 0.00 | -- | -- | 0.00 | -97.69 | -125.27 | -116.81 | -- | -- | -- | -- | -830.46 | -- | -- | 0.00 | -- | -95.29 | -- | -5.56 | -- | -26.46 | -- |
| Cardiff Oncology Inc | 593.00k | -45.88m | 132.63m | 31.00 | -- | 2.92 | -- | 223.66 | -0.6873 | -0.6873 | 0.0089 | 0.6645 | 0.0075 | -- | 1.24 | 19,129.03 | -57.65 | -36.79 | -70.95 | -40.48 | -- | -- | -7,732.04 | -7,960.06 | -- | -- | 0.00 | -- | -13.18 | 10.13 | -0.9262 | -- | -26.97 | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 132.94m | 13.00 | 3.32 | 0.671 | 3.03 | 66.47 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Polaryx Therapeutics, Inc | -100.00bn | -100.00bn | 136.35m | 2.00 | -- | 25.72 | -- | -- | -- | -- | -- | 0.112 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -703.28 | -- | -- | -- |
| Immunic Inc | 0.00 | -97.17m | 138.29m | 92.00 | -- | -- | -- | -- | -0.6855 | -0.6855 | 0.00 | -0.0554 | 0.00 | -- | -- | 0.00 | -299.36 | -110.19 | -1,602.57 | -137.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.32 | -- | 1.98 | -- |
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 138.45m | 24.00 | 6.70 | 1.10 | 6.34 | 1.98 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 139.76m | 62.00 | -- | 2.52 | -- | 183.41 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 140.20m | 23.00 | -- | 1.99 | -- | 8,247.18 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 141.62m | 106.00 | -- | 1.10 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
Data as of Mar 02 2026. Currency figures normalised to Cardiff Oncology Inc's reporting currency: US Dollar USD
25.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.69m | 5.48% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.25m | 4.82% |
| Laurion Capital Management LPas of 31 Dec 2025 | 2.65m | 3.93% |
| William Blair & Co. LLC (Investment Management)as of 31 Dec 2025 | 1.95m | 2.89% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.52m | 2.26% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 1.21m | 1.79% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.19m | 1.77% |
| Two Sigma Investments LPas of 31 Dec 2025 | 724.96k | 1.08% |
| F.L. Putnam Investment Management Co.as of 31 Dec 2025 | 595.33k | 0.88% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 461.75k | 0.69% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
